Lung function with aclidinium/formoterol fixed-dose combination: Pooled analysis of two phase III studies in COPD

Conclusion: Both doses of aclidinium/formoterol FDC demonstrated rapid, sustained improvements in lung function over 24 weeks versus placebo and the monotherapies in patients with COPD.

Source: European Respiratory Journal - October 30, 2015 Category: Respiratory Medicine Authors: Singh, D., D'Urzo, A. D., Donohue, J. F., Chuecos, F., Leselbaum, A., Gil, E. G. Tags: 5.1 Airway Pharmacology and Treatment Source Type: research